Most recent guideline publication:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016)
Updates since publication:
No updates on dosing recommendations since publication.
Tables provided in the main manuscript of the guideline:
|Table 1. Assignment of likely CYP2C19 phenotype based on genotypes|
|Table 2. Dosing recommendations for voriconazole based on CYP2C19 phenotype for adult patients|
|Table 3. Dosing recommendations for voriconazole based on CYP2C19 phenotype for pediatric patients (children and adolescents <18 years old)|
Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016)
Tables and figures provided in the guideline publication supplement or referenced in the guidelinea:
|Supplemental Table S1. Evidence linking CYP2C19 genotype to voriconazole phenotype|
|CYP2C19 allele definition table|
|CYP2C19 allele functionality table|
|CYP2C19 frequency table|
|CYP2C19 diplotype-phenotype table|
|Gene resource mapping|
|Drug resource mapping|
|Clinical decision support:b|
aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.
bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.
This guideline has been endorsed by the American Society of Health-System Pharmacists (ASHP).